Expression of YAP1 and SOX2 in epithelial ovarian carcinoma and their clinical significance
NI Xiao-ge1, YANG Pei-fang2
(1. Department of Gynaecology and Obstetrics, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002; 2. Department of Gynaecology and Obstetrics, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China)
摘要目的: 检测卵巢上皮性癌中Yes相关蛋白1(Yes-associated protein1, YAP1)和Y染色体性别决定区相关的高迁移率族盒蛋白2(sexdeterming region of Y chromosome related high mobility group box 2，SOX2)的表达及意义。方法: 选取86例卵巢上皮性癌组织和20例行卵巢活检的正常卵巢组织(少数局灶伴良性上皮性囊肿)，采用免疫组织化学法检测YAP1和SOX2的表达；记录并统计86例卵巢癌患者的生存时间、肿瘤相关的临床病理参数，分析其与YAP1高表达的关系；建立SOX2稳定转染的卵巢上皮癌细胞株，免疫印迹法检测SOX2及YAP1的表达，划痕实验检测SOX2过表达细胞的迁移能力。结果： 卵巢上皮性癌中YAP1和SOX2的高表达率明显高于正常卵巢组织(P均＜0.01)；YAP1高表达患者生存时间明显短于低表达者(P＜0.01)；卵巢上皮性癌组织中YAP1高表达与年龄无关，但与化疗耐药、肿瘤转移、FIGO分期、组织分化相关。YAP1和SOX2表达与卵巢上皮性癌相关，且两者表达呈正相关(r=0.635，P＜0.01)。与对照组比较，SOX2过表达细胞中YAP1蛋白表达明显增加(t=6.304，P＜0.01)，细胞迁移能力明显提高(t=11.77，P＜0.01)。结论： YAP1和SOX2在卵巢上皮性癌中呈高表达，且与卵巢上皮性癌发生发展相关。
Abstract：Objective： To investigate the expression of Yesassociated protein1(YAP1) and sex-determining region of Y chromosome related high mobility group box 2(SOX2) and their significance in epithelial ovarian carcinoma. Methods： The expression of YAP1 and SOX2 in 86 cases of ovarian carcinoma, and 20 cases of normal ovarian tissue were examined by immunohistochemical staining. Survival time, tumor related clinicopathological parameters of patients with ovarian cancer were recorded, and their correlation with YAP1 expression was statistically analyzed. The epithelial ovarian cancer cell lines which stable transfected with SOX2 were established; the expression of SOX2 and YAP1 in the stable cell lines were determined by Western blotting; the migration ability of cells was determined by wound healing assay. Results： The overexpression ratios of YAP1 and SOX2 in ovarian cancer were higher than that in normal ovarian tissue(P＜0.01). Patients with high-expression YAP1 had shorter survival time than those with lowexpression YAP1(P＜0.01). The overexpression of YAP1 showed correlation with chemotherapy resistance, metastasis, FIGO stage, and tissue differentiation, but showed no correlation with age. YAP1 overexpression was positively correlated with SOX2 overexpression (r=0.635, P＜0.01). Comparison with control group, overexpressionSOX2 cells showed higher expression of YAP1(t=6.304, P＜0.01), elevated migration ability(t=11.77,P＜0.01). Conclusion：YAP1 and SOX2 were highly expressed and correlated in epithelial ovarian cancer, which related to the prognosis of epithelial ovarian cancer.
收稿日期: 2016-02-29
基金资助:
镇江市社会发展项目(SH2011020)
通讯作者:
杨佩芳(通讯作者)，副教授，硕士生导师，E-mail: ypf@ujs.edu.cn
作者简介: 倪晓鸽(1981—)，女，硕士研究生；
引用本文:
倪晓鸽1， 杨佩芳2. 卵巢上皮性癌YAP1和SOX2的表达及其临床意义[J]. 江苏大学学报:医学版, 2016, 26(05): 405-409.
NI Xiao-ge1, YANG Pei-fang2. Expression of YAP1 and SOX2 in epithelial ovarian carcinoma and their clinical significance. Journal of Jiangsu University(Medicine Edition), 2016, 26(05): 405-409.
［1］李英汉. 尿液HE4联合CA125检测对卵巢癌细胞的价值分析\[J\]. 吉林医学，2015，36(5)：884-885.［2］Barger CJ, Zhang W, Hillman J, et al. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression\[J\]. Oncotarget, 2015, 6(29): 27613-27627.［3］Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes\[J\]. Nat Rev Cancer, 2011,11(10):719-725.［4］Shih Iem, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis\[J\]. Am J Pathol, 2004, 164(5): 1511-1518.［5］Yabuta N, Okada N, Ito A, et al. Lats2 is an essential mitotic regulator required for the coordination of cell division\[J\]. J Biol Chem, 2007, 282(26):19259-19271.［6］Jeong W, Kim SB, Sohn BH, et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer\[J\]. Anticancer Res, 2014, 34(2): 811-817.［7］Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer\[J\]. Nat Rev Cancer, 2013,13(4): 246-257.［8］Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic\[J\]. Clin Transl Med, 2014, 3: 19.［9］Seo E, BasuRoy U, Gunaratne PH, et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteoadipo lineage\[J\]. Cell Rep, 2013, 3(6): 2075-2087.［10］Nuzzo PV, Rubagotti A, Zinoli L, et al. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death\[J\]. BMC Cancer, 2012, 12: 625.［11］张广杰, 张晓刚. 转录因子SOX2在常见肿瘤研究中的新进展\[J\]. 重庆医学, 2012, 41(21): 2221-2223.［12］Kim SK, Jung WH, Koo JS. Yesassociated protein(YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer\[J\]. Int J Clin Exp Pathol, 2014, 7(6): 3224-3234.［13］Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development\[J\]. J Hepatol, 2014, 61(5): 1088-1096.［14］Xia Y, Chang T, Wang Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients\[J\]. PLoS One, 2014, 9(3): e91770.［15］吴卉, 花荣, 陈锦先. Hippo通路及靶因子YAP与肿瘤关系的研究进展\[J\]. 实用医学杂志, 2013, 29(4):515-517.［16］BasuRoy U, Bayin NS, Rattanakorn K, et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells\[J\]. Nat Commun, 2015, 6: 6411.
2016, Vol. 26 
